Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 8;22(1):2294.
doi: 10.1186/s12889-022-14794-2.

SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May-June, 2021

Yao Rodion Konu  1   2   3   4 , Siaka Condé  5 , Fifonsi Gbeasor-Komlanvi  2   3   4 , Arnold Junior Sadio  2   3   4 , Martin Kouame Tchankoni  2   3   4 , Joel Anani  5 , Alexandra Bitty-Anderson  1   4 , Bisimwa Ruhana Mirindi  5 , Fatoumata Binta Tidiane Diallo  5 , Moustapha MIjiyawa  6 , Anoumou Claver Dagnra #  7 , Didier Koumavi Ekouevi #  8   9   10   11
Affiliations

SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May-June, 2021

Yao Rodion Konu et al. BMC Public Health. .

Erratum in

Abstract

Background: The extent of SARS-CoV-2 circulation in African countries is still unclear. Seroprevalence studies are a common approach to epidemiological surveillance, allowing estimation of the proportion of people who have had contact with the virus. We aimed at estimating the seroprevalence of anti-SARS-CoV-2 antibodies and associated factors in Togo at the national level in 2021 according to age groups, gender, and place of residence (rural or urban).

Methods: From 15 May to 31 June 2021, we conducted a nationally representative cross-sectional serological survey in 12 health districts (two districts per health region) in the > 5 years old population in Togo. The Wantai SARS-CoV-2 total antibody assay S protein receptor-binding domain-based ELISA (Wantai Biological Pharmacy Enterprise Co.; Beijing, China) was used to determine the presence of SARS-CoV-2 total antibodies in plasma. Crude and weighted seroprevalences (weighted by age, sex and place of residence) were calculated and then weighted seroprevalences were adjusted according to sensitivity and specificity of the ELISA test. Finally, logistic regression models were performed in order to describe factors associated.

Results: Of the 7593 participants, the overall weighted and adjusted seroprevalence of total anti-SARS-CoV-2 antibodies was 65.5% (CI95%: 18.9-21.1). Urban dwellers, young adults (30-49 years) and vaccinated individuals were significantly more likely to be seropositive.

Conclusion: The high seroprevalence we observed is consistent with observations across West Africa. Quantification of the level of immunity in the population is needed to know how close we are to herd immunity. In the meantime, vaccination against the COVID-19 remains necessary.

Keywords: General population; SARS-CoV-2; Seroprevalence; Togo.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Seroprevalence by district, Sero-CoV survey, May–June 2021
Fig. 2
Fig. 2
Factors associated with the presence of anti-SARS-CoV-2 antibodies, final multivariate models, Sero-CoV Togo survey, March – June 2021 (A- whole sample (N = 7593), B-vaccinated subjects (N = 1316), C- unvaccinated subjects (N = 4924)). *The final multivariable model for B is better adjusted without the age variable
See this image and copyright information in PMC

References

    1. WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int. [cited 26 Apr 2022].
    1. Alwan NA. Surveillance is underestimating the burden of the COVID-19 pandemic. Lancet. 2020;396(10252):e24. doi: 10.1016/S0140-6736(20)31823-7. - DOI - PMC - PubMed
    1. Adebisi YA, Rabe A, Lucero-Prisno Iii DE. COVID-19 surveillance systems in African countries. Health Promot Perspect. 2021;11(4):382–392. doi: 10.34172/hpp.2021.49. - DOI - PMC - PubMed
    1. Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, Li Z, Ma X, Valenciano M, Cheng B, Al Ariqi L, Rashidian A, Okeibunor J, Azim T, Wijesinghe P, Le LV, Vaughan A, Pebody R, Vicari A, Yan T, Yanes-Lane M, Cao C, Clifton DA, Cheng MP, Papenburg J, Buckeridge D, Bobrovitz N, Arora RK, Van Kerkhove MD; Unity Studies Collaborator Group. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022;19(11):e1004107. 10.1371/journal.pmed.1004107. - PMC - PubMed
    1. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252617. doi: 10.1371/journal.pone.0252617. - DOI - PMC - PubMed

Substances